This measure directs the Secretary of Health and Human Services, through the National Institutes of Health and the Health Resources and Services Administration, to expand research, surveillance, education, and training related to Premenstrual Dysphoric Disorder (PMDD). It calls for more clinical trials, better data collection on how common PMDD is and its economic impact, a public awareness campaign to reduce stigma and encourage care, continuing education for health providers, and grants to train clinicians. The bill also requires a report to Congress on progress within two years.
If enacted, federal health agencies would work to fund and coordinate more PMDD research and public information. Health care providers could receive new training and continuing education about diagnosing and treating PMDD. Some hospitals, medical schools, nursing and pharmacy programs, and related training programs could apply for grants to expand PMDD clinical training. The bill orders new data collection about PMDD prevalence, barriers to care, and economic effects.
The bill does not list dollar amounts. Instead, it authorizes "such sums as is necessary" for specified fiscal years: section 3 (research and surveillance) for fiscal years 2027 through 2031; section 4 (education and awareness) for fiscal years 2026 through 2030; section 5 (training grants) for fiscal years 2027 through 2031; and section 6 (report) for fiscal years 2027 through 2031. No specific cost estimates are provided in the text.
The bill states that PMDD affects an estimated 5 to 8 percent of people assigned female at birth of reproductive age, can be severe and disabling, and is often under-diagnosed and stigmatized. Proponents in the text argue that expanding research, improving provider knowledge, raising public awareness, and increasing access to diagnosis and treatment are necessary to improve quality of life for people with PMDD.
No publicly available information.